- Trial phase
- Preclinical
- Time to market
- Not stated
- Why 4/10
- XTX701 is a wholly-owned preclinical masked T cell engager with no announced IND filing timeline, no clinical trial registration, and no hard dated catalyst (PDUFA, readout, or AdComm) in the next ~12 months. The next meaningful disclosure would likely be a preclinical data presentation at a scientific conference, but no venue or date has been announced. XTX701 is one of several pipeline programs at Xilio and is earlier-stage than XTX501 (Phase 1/2) and XTX601 (IND-enabling). Impact score is capped at 4 per the rubric because no binary catalyst is scheduled.
XTX701 is a preclinical masked T cell engager with no IND submission timeline publicly disclosed. Investors should watch for Xilio's next corporate update or scientific conference presentation for any advancement of this program into IND-enabling studies. The nearer-term catalyst for Xilio is the Phase 1 data readout for XTX501 expected in Q4 2027, which carries more weight for the stock. XTX701-specific preclinical data could emerge at a future conference but no venue has been announced.
Price Chart
Executive Summary
XTX701 is Xilio Therapeutics' wholly-owned preclinical masked T cell engager targeting the prostate cancer antigens PSMA and STEAP1. The program is in early-stage research and development, with no IND filed, no clinical trial registered, and no hard dated catalyst in the next 12 months. Xilio's masking platform is designed to activate T cells only within the tumor microenvironment to reduce systemic toxicity, and the company optimized XTX701 by screening over 1,800 molecules. The program benefits from external validation via an AbbVie collaboration on masked T cell engagers ($52M upfront), but remains early-stage and preclinical. For a micro-cap company (~$60M market cap) with cash runway into Q1 2028, XTX701 is one of several pipeline candidates, behind XTX501 (Phase 1/2) and XTX601 (IND-enabling) in priority. The stock has analyst consensus of 2 Strong Buy, 3 Buy, and 1 Hold with a mean price target of $18 (123% upside), but XTX701-specific catalysts are too distant to drive near-term value.
How It Works
XTX701 is a type of immunotherapy known as a masked T cell engager. It is designed as a bispecific molecule (it has two different binding arms) that simultaneously targets two proteins found on prostate cancer cells (PSMA and STEAP1) while also grabbing hold of immune T cells (via CD3). Xilio's masking technology keeps the molecule inactive in healthy tissues and only activates it inside the tumor environment. This approach aims to direct the patient's own immune T cells to destroy prostate cancer cells while reducing the severe inflammatory side effects that normally limit T cell engager drugs. The drug was developed by screening over 1,800 candidate molecules to find the optimal design.
Trial Status
XTX701 is in preclinical development. No IND application has been filed and no clinical trials are registered on ClinicalTrials.gov. Xilio's management discussed the program at the Stifel 2026 Healthcare Conference, noting it was optimized from over 1,800 molecules for geometry and target binding to PSMA, STEAP1, and CD3. The company has not announced a timeline for IND submission or first-in-human studies for XTX701. The more advanced masked T cell engager program, XTX601 (targeting CLDN18.2), has IND-enabling studies underway with an IND submission planned for 2027.
The Two-Sided Case
Upcoming Catalysts
- No dated catalyst announced for XTX701 specifically. A preclinical data presentation at a future scientific conference is possible but no venue or date has been disclosed.
- For context on Xilio's pipeline: initial Phase 1 data for XTX501 (PD-1/masked IL-2 bispecific) expected in Q4 2027; IND submission for XTX601 (CLDN18.2 masked TCE) planned for 2027.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Xilio Therapeutics, Inc. PRESS-RELEASE XLO ·Originating report